<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" VersionDate="2021/08/27" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">34621523</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review.</ArticleTitle><Pagination><StartPage>1455</StartPage><MedlinePgn>1455</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1455</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.27284.2</ELocationID><Abstract><AbstractText>Although the majority of people with Covid-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms for months after the acute phase of the illness. These symptoms include, among others, fatigue, problems breathing, lack of smell and taste, headaches, and depression and anxiety. It is also clear the virus has lasting fluctuating multiorgan sequelae, including affecting not only the respiratory system but also the heart, liver, and nervous system. We present a protocol for a living&#xa0;systematic review that aims to synthesize the evidence on the prevalence and characteristics of post-acute COVID-19. The living systematic review will be updated regularly, approximately every 6 months, as new evidence emerges. We will include studies that follow up at least 100 people with Covid-19 at 12 or more weeks post Covid-19 onset, with no restrictions regarding country, setting, or language. We will use descriptive statistics and, for outcomes reported in two or more studies, we will use meta-analyses to estimate prevalence with 95% confidence intervals (CIs) using the exact method. Heterogeneity between estimates will be assessed using the I2 statistic. Our findings will also be presented as infographics to facilitate transcription to lay audiences. Ultimately, we aim to support the work of policy makers, practitioners, and patients when planning rehabilitation for those recovering from Covid-19. The protocol has been registered with PROSPERO (&#xa0; CRD42020211131, 25/09/2020).</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Michelen M et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michelen</LastName><ForeName>Melina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health Sciences, City, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manoharan</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkheir</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1786-8530</Identifier><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagens</LastName><ForeName>Drew</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hastie</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2075-2130</Identifier><AffiliationInfo><Affiliation>Long Covid Support, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hara</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Long Covid Support, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suett</LastName><ForeName>Jake C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Long Covid Support, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Elizabeth Hospital Kings Lynn, Norfolk, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahmash</LastName><ForeName>Dania</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6508-0994</Identifier><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugaeva</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigby</LastName><ForeName>Ishmaela</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munblit</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Clinical Center for Neuropsychiatry, Moscow, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harriss</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bodleian Health Care Libraries, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burls</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Health Sciences, City, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foote</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Independent Editor, Soquel, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olliaro</LastName><ForeName>Piero</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigfrid</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavropoulou</LastName><ForeName>Charitini</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4307-1848</Identifier><AffiliationInfo><Affiliation>School of Health Sciences, City, University of London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Living systematic review</Keyword><Keyword MajorTopicYN="N">lasting effects</Keyword><Keyword MajorTopicYN="N">long covid</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34621523</ArticleId><ArticleId IdType="pmc">PMC8459620</ArticleId><ArticleId IdType="doi">10.12688/f1000research.27284.2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC:
Coronavirus Disease 2019 (COVID-19). 
Cent Dis Control Prev.
 2020; (accessed 6 Aug 2020).
Reference Source</Citation></Reference><Reference><Citation>Michelen M, Jones N, Stavropoulou C:
In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases?(accessed 6 Aug 2020).
Reference Source</Citation></Reference><Reference><Citation>Rayner C, Lokugamage AU, Molokhia M:
Covid-19: Prolonged and relapsing course of illness has implications for returning workers.2020; (accessed 6 Aug 2020).
Reference Source</Citation></Reference><Reference><Citation>Garner P:
Paul Garner: Covid-19 at 14 weeks&#x2014;phantom speed cameras, unknown limits, and harsh penalties. The BMJ.(accessed 6 Aug 2020).
Reference Source</Citation></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. : Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, et al. : Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW: Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network &#x2014; United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998. 10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Cevik M, Jesudason E, et al. : What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study. medRxiv. 2020. 10.1101/2020.08.26.20180950</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.26.20180950</ArticleId><ArticleId IdType="pmc">PMC7948153</ArticleId><ArticleId IdType="pubmed">33692181</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England and NHS Improvement:
After-care needs of inpatients recovering from COVID-19.2020; (accessed 24 Sep 2020).
Reference Source</Citation></Reference><Reference><Citation>British Society for Immunology:
COVID-19 immunology briefing note: What we know about long-term health consequences and priorities for research. Immunology. 2020.
Reference Source</Citation></Reference><Reference><Citation>Elliott JH, Synnot A, Turner T, et al. : Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017;91:23&#x2013;30. 10.1016/j.jclinepi.2017.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.08.010</ArticleId><ArticleId IdType="pubmed">28912002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, et al. : Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. 10.1186/s13643-016-0384-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, et al. : Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934&#x2013;9. 10.1016/j.jclinepi.2011.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.11.014</ArticleId><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. : Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. 10.1186/2046-4053-4-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Sigfrid L, Manoharan L, et al. : What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review.City, University of London. Journal contribution.2020. 10.25383/city.13187456.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.25383/city.13187456.v1</ArticleId><ArticleId IdType="pmc">PMC8459620</ArticleId><ArticleId IdType="pubmed">34621523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>